Fate can be altered
Discovering and developing first-in-class small molecule drugs for improved treatment of diseases with significant clinical need.More info More info
We aim to become globally recognized for developing breakthrough therapies to treat incurable diseases. Through intelligent identification and validation of protein and mRNA targets that drive disease progression and modulating their activity with small molecules, we strive to change the fate of patients by stopping the progression and reversing the effects of diseases with unmet medical need.More info More info
Molecure’s exceptional in-house medicinal chemistry, biology and discovery capabilities allied to novel target biology gained from leading universities worldwide has enabled us to create a broad pipeline of drug candidates targeting unique and unexplored protein targets, as well as a cutting-edge small molecule mRNA targeting discovery platform.Discover our pipeline Discover our pipeline
On the 28th March 2022, OncoArendi changed its name to Molecure
Invitation to investor meeting 3rd October 2023, 2:00 pm (CET)
Molecure submits application to the European Medicines Agency (EMA) to initiate a phase II clinical trial in the European Union and Norway to investigate OATD-01 for the treatment of pulmonary sarcoidosis
The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch
People are the foundation of Molecure’s success. Our scientists are the creators of the best ideas for the multiple new small molecule medicines that are invented in the laboratories. The Molecure team works together to discover the therapies needed to improve the treatment of previously incurable diseases.
It is this unified goal that guides us every day. We are inspired by science, we discover and create. For us, work is a passion.